| Morris, David |
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent |
|
|
| Terminated | 3 | 105 | US | VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga | Veru Inc. | Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer | 05/23 | 05/23 | | |
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy |
|
|
| Recruiting | 3 | 383 | US, RoW | 64Cu-SAR-bisPSMA | Clarity Pharmaceuticals Ltd | Prostate Cancer, Prostatic Neoplasms | 02/25 | 02/25 | | |
NCT05829460: Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia |
|
|
| Not yet recruiting | 2 | 96 | US | Semaglutide, Placebo, LNG-IUD (Progestin), Telemedicine behavioral weight program | Washington University School of Medicine, Novo Nordisk A/S | Endometrial Hyperplasia | 12/29 | 12/31 | | |
| Terminated | 1/2 | 102 | Europe, US | Tazemetostat, EPZ-6438, E7438, IPN60200, Abiraterone/prednisone, Zytiga, Enzalutamide, Xtandi | Epizyme, Inc. | Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | 11/24 | 11/24 | | |
|
|
| Recruiting | 1 | 174 | US | PRL-02 injection, prednisone, dexamethasone, enzalutamide | Astellas Pharma Global Development, Inc. | Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer | 08/25 | 05/29 | | |
NCT06310278: Ossiview Normative Mobility Data Collection Protocol |
|
|
| Recruiting | N/A | 120 | Canada | Ossicular mobility measurement | Audioptics Medical Incorporated | Conductive Hearing Loss, Middle Ear | 10/24 | 10/24 | | |
| Jayram, Gautam |
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin |
|
|
| Recruiting | 3 | 190 | Japan, US, RoW | Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM | CG Oncology, Inc. | Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer | 12/27 | 12/29 | | |
UTOPIA, NCT06331299: A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer |
|
|
| Recruiting | 3 | 87 | US | UGN-103, UGN-103 (mitomycin) for intravesical solution | UroGen Pharma Ltd. | Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder | 07/25 | 07/26 | | |
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following |
|
|
| Recruiting | 3 | 364 | Canada, US | Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM | CG Oncology, Inc. | Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma | 01/28 | 01/30 | | |
NCT06567743: Brief Title: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC |
|
|
| Recruiting | 2 | 50 | US | Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM | CG Oncology, Inc. | High-Risk Non-Muscle-Invasive Bladder Cancer | 03/27 | 12/27 | | |
NCT03945162: Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients |
|
|
| Recruiting | 2 | 125 | Canada, US | Ruvidar® (TLD-1433) Bladder infusion and PDT | Theralase® Technologies Inc., University Health Network, Toronto, Pharma eMarket | Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG | 06/25 | 12/25 | | |
NCT05710848: A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer |
|
|
| Recruiting | 1/2 | 75 | US | STM-416 | SURGE Therapeutics | Non-muscle-invasive Bladder Cancer | 12/25 | 12/25 | | |
